RA Cap­i­tal leads $125M for Janux in VC's lat­est crossover bid

Four months ago, on­ly a short list of peo­ple had ever heard of Janux Ther­a­peu­tics. To­day, they have a part­ner­ship with Mer­ck, $212 mil­lion in VC cap­i­tal and, it seems, plans for an IPO.

Janux an­nounced Tues­day a $125 mil­lion crossover round led by RA Cap­i­tal, the Boston VC be­hind a spate of re­cent pre-IPO fi­nanc­ings. Janux de­clined an in­ter­view re­quest, a com­mon move for biotechs prepar­ing to go pub­lic in the near fu­ture.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN